🇺🇸 FDA
Patent

US 11279686

Nrf2 activating compounds and uses thereof

granted A61PA61P17/06A61P25/00

Quick answer

US patent 11279686 (Nrf2 activating compounds and uses thereof) held by Rigel Pharmaceuticals, Inc. expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61P, A61P17/06, A61P25/00, A61P29/00, A61P37/00